LTZ Therapeutics Strengthens Scientific Advisory Board with Global 'Dream Team' to Accelerate Next-Generation Immunotherapies for Cancer and Complex Diseases

June 14, 2022, Shenzhen, China, and Palo Alto, California, USA — LTZ Therapeutics (referred to as “LTZ”), today announced that Dr. Lillian L. Siu and Dr. Stephen Beers have officially joined the company’s Scientific Advisory Board (SAB), following Dr. Sarah Hymowitz, Dr. Greg Cosma, and Dr. Lukas Amler.

At this point, LTZ has formed an SAB "dream team" composed of top industry leaders worldwide, including:

Dr. Stephen Beers: Renowned tumor immunologist and tumor biologist.Stephen serves as a Professor of Immunology and Immunotherapy at the Centre for Cancer Immunology within the Faculty of Medicine at the University of Southampton in the UK. His key research areas include how to modulate Treg-mediated immunosuppression mechanisms within the tumor microenvironment, how to better regulate macrophage-mediated immune killing functions, and more. This aligns closely with LTZ Therapeutics' three-pronged R&D strategy (reducing immunosuppression, reprogramming innate immunity, and modulating adaptive immunity), holding promise to accelerate the development of innovative drugs that can both overcome drug resistance and recurrence and enhance anti-tumor immunity.

Dr. Sarah Hymowitz: World-class antibody discovery experts and drug development experts.Before becoming an investment partner at the Column Group, Sarah worked at Genentech for 22 years. As the Vice President of Protein Sciences, she was responsible for all large molecule drug discovery, designing and optimizing countless clinical candidates. For an antibody company like LTZ Therapeutics, which focuses on immunotherapy, the discovery of protein drugs and antibody optimization in all dimensions are the cornerstones of drug success.

Dr. Lukas Amler: With over30Years of experienceOncology Drug Translational DevelopmentExperts and Companion Diagnostics Experts。LukasRecently18YearInGenentechAsTumor Marker（Oncology Biomarkers）Executive Director Leads Transformation and Development. Prior to this, he was at Bristol-Myers Squibb (BMS) served as the pharmacogenomics (Pharmacogenomics）Deputy Director.LukasAbundant practical experience in translational medicine and reverse translational medicine will guideLTZTarget the right development direction through human-derived data, and select targets and indications with higher druggability.

Dr. Greg Cosma: A senior expert with over 20 years of leadership in developing strategies and regulatory frameworks in the pharmaceutical industry.Greg has held leadership positions in several top multinational pharmaceutical companies, including serving as Vice President of Development Sciences at Genentech. He has a deep understanding of the rapidly evolving regulatory systems in major pharmaceutical markets and is skilled at comprehensively integrating dimensions such as regulatory guidelines, pharmacology, toxicology, and biomarkers to plan the optimal drug development pathway. He will "tailor-make" the most suitable systematic development strategy for each drug molecule at LTZ Therapeutics.

Dr. Lillian L. Siu: A world-renowned oncologist and clinical development expert.Since 1998, she has been practicing at the Princess Margaret Cancer Centre (the largest integrated cancer research, teaching, and treatment center in Canada) and has been a professor of medicine at the University of Toronto since 2009. Lillian holds significant influence in the global oncology field across industry, research, academia, and regulation. She has served as a board member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). In addition to publishing 370+ peer-reviewed papers, she is the editor-in-chief of AACR's *Cancer Research Communications*, a scientific editor of *Cancer Discovery*, and an editorial board member of top international journals such as *JAMA Oncology*, *Cell*, and *Cancer Cell*. In the development of novel immuno-oncology drugs by many leading multinational pharmaceutical companies, Lillian has been entrusted with critical responsibilities, leading the most challenging Phase I exploratory trials. For LTZ Therapeutics, Lillian’s guidance will be a strong backbone for the company’s innovative immunotherapy drugs to successfully pass the first-in-human trials.

Particularly important is that this SAB team not only consists of top Key Opinion Leaders (KOLs) in their respective fields, but also their expertise is highly complementary, creating a powerful synergistic effect where 1+1>2 when combined — from immunological mechanism research, early antibody discovery, tumor marker exploration, development strategy formulation based on regulatory guidelines across various countries, to clinical development advancement. The five SAB members correspond respectively to the five core modules of innovative immunotherapy drug development. When these five pieces fit together seamlessly, they form a complete closed loop with no gaps, achieving comprehensive coverage of all aspects of the new drug development process.

Why did LTZ make great efforts to build a heavyweight SAB "dream team" in its early entrepreneurial stage? This stems from the company's clear self-positioning and well-defined goals — for a biotechnology company like LTZ Therapeutics, which is committed to developing "first-in-class" and "best-in-class" innovative drugs, the significant importance of bringing in an SAB as early as possible can be reflected in at least the following four aspects:

To achieve breakthrough innovation from 0 to 1, the development of first-in-class drugs is destined to be an exploration in uncharted territory. Facing unprecedented unknown fields, with the precise control and guidance of SAB at the source of innovation, enterprises can avoid pitfalls, collisions, and detours, reduce trial-and-error costs, increase success rates, and thereby quickly find the right direction through the fog and thorns, paving an entirely new path.

In the field of translational medicine, SAB can systematically guide enterprises to transform scientific understanding of basic research on pathogenesis, progression pathways, and drug mechanisms into the design of compounds that are rational, safe, effective, technologically feasible, and cost-controllable, while continuously optimizing drug molecules. This builds a bridge from bench to bedside.

Patient-centered and clinical value-oriented represent the original aspiration and ultimate goal of enterprises in developing new drugs. SAB can integrate unmet clinical needs, real-world data, characteristics of candidate drugs, regulatory requirements, and other elements to help companies accurately match the most suitable targets, indications, and clinical development strategies.

The front-line clinical experts in SAB have long accumulated keen insights, profound understanding, and forward-looking predictions on the demand side (epidemiological dynamics, trends in clinical needs), supply side (competitive landscape, strengths and weaknesses of marketed/pipeline competitors), distribution side, and payment side. This expertise is expected to assist companies in precisely targeting differentiated market positioning for their pipelines, supporting corporate financing and future product commercialization. This is crucial for the long-term sustainable development of research-driven biotechnology companies.

In short, with the strong support of the SAB expert team, LTZ Therapeutics is expected to shape the spirit of innovation, build the backbone of science, alleviate clinical pain points, and create a new commercial landscape. In doing so, it will fulfill its solemn commitment to patients, the industry, and itself—exhausting all efforts to scientifically explore breakthroughs in existing treatment bottlenecks, design and develop safe and effective original drugs, and seek entirely new solutions for the unmet clinical needs of a broad patient population.

"We are extremely grateful to have five world-class industry leaders join LTZ's SAB, providing guidance and support for our continuous development of first-in-class innovative drugs," said Dr. Robert Li, Co-founder and CEO. "This not only fully affirms the innovation capability and translational potential of our R&D platform but also carries high expectations and strong encouragement for us. We look forward to collaborating closely with the SAB expert team to accelerate the development of breakthrough next-generation immunotherapies, benefiting patients worldwide suffering from cancer and other complex diseases."

LTZ Therapeutics is a globally leading, fully integrated biotechnology company co-founded by three pioneering figures in new drug development: Dr. Jinze Li (Dr. Robert Li), Dr. Martin Treder, and Dr. Jianhui Zhou. Targeting cancer and other complex diseases with significant unmet clinical needs, LTZ focuses on immunotherapy to develop innovative original drugs and systematically enhance patient clinical benefits. The company’s international team is located in Shenzhen, China; Palo Alto, California, USA; and Heidelberg, Germany. Based on reverse translational science and emerging tumor microenvironment biology, LTZ is committed to developing next-generation immunotherapies that can both overcome drug resistance and recurrence and enhance anti-tumor immunity.